share_log

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

再鼎医药(纳斯达克:ZLAB)有债务但没有盈利,你应该担心吗?
Simply Wall St ·  07/19 09:21

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. Importantly, Zai Lab Limited (NASDAQ:ZLAB) does carry debt. But the real question is whether this debt is making the company risky.

大卫·艾本说得好:“波动率并不是我们所关心的风险。我们关心的是避免永久性资本损失。”看起来理智的投资者知道,债务——通常是破产的因素——是评估公司风险的一个非常重要的因素。重要的是,再鼎医药(纳斯达克:ZLAB)确实持有债务。但真正的问题是,这些债务是否使公司产生风险。

When Is Debt Dangerous?

债务何时有危险?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

债务能够在公司遇到困难时提供帮助,如果公司无法通过新资本或自由现金流偿还债务,则这些债务将最终导致股东损失惨重。然而,更常见(但仍然痛苦)的情况是,公司按低价发行新的股权资本,从而永久性地稀释股东的权益。当然,有很多公司使用债务来资助公司的成长,而没有任何负面的后果。因此,在考虑公司使用多少债务时,首先要看其现金和债务合起来。

How Much Debt Does Zai Lab Carry?

再鼎医药承担了多少债务?

The image below, which you can click on for greater detail, shows that at March 2024 Zai Lab had debt of US$48.3m, up from none in one year. But on the other hand it also has US$650.8m in cash, leading to a US$602.5m net cash position.

下面的图片可以点击以查看更多详细信息。截至2024年3月,再鼎医药的债务总计为4830万美元,而一年前则没有债务。另一方面,它还有65080万美元的现金,因此净现金为60250万美元。

big
NasdaqGM:ZLAB Debt to Equity History July 19th 2024
纳斯达克:ZLAb资本结构债务股本比历史数据2024年7月19日

How Strong Is Zai Lab's Balance Sheet?

再鼎医药的资产负债表如何?

According to the last reported balance sheet, Zai Lab had liabilities of US$192.1m due within 12 months, and liabilities of US$34.2m due beyond 12 months. Offsetting these obligations, it had cash of US$650.8m as well as receivables valued at US$75.8m due within 12 months. So it actually has US$500.3m more liquid assets than total liabilities.

根据最后披露的资产负债表,再鼎医药有19210万美元的负债到期,超过12个月则为3420万美元。对冲这些义务,它有65080万美元的现金以及7580万美元的应收款项到期回收。所以它实际上比总负债多出50030万美元的流动资产。

This surplus suggests that Zai Lab is using debt in a way that is appears to be both safe and conservative. Given it has easily adequate short term liquidity, we don't think it will have any issues with its lenders. Simply put, the fact that Zai Lab has more cash than debt is arguably a good indication that it can manage its debt safely. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Zai Lab's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

这种盈余表明再鼎医药的债务使用方式看起来既安全又保守。由于其短期流动性充足,我们认为它不会在与贷款人的关系上遇到任何问题。简而言之,再鼎医药的现金超过债务,这可以被认为是它能够安全地管理债务的一个好迹象。在分析债务水平时,资产负债表是开始的明显位置。但最终决定再鼎医药能否维持健康的资产负债表的关键因素,是未来的盈利能力。所以,如果你专注于未来,你可以查看这份免费报告,其中显示了分析师利润预测。

Over 12 months, Zai Lab reported revenue of US$291m, which is a gain of 26%, although it did not report any earnings before interest and tax. With any luck the company will be able to grow its way to profitability.

在过去的12个月中,再鼎医药报告了2.91亿美元的营业收入,增长了26%,虽然它没有报告任何利润。希望公司能够实现盈利。

So How Risky Is Zai Lab?

那么再鼎医药的风险如何?

Statistically speaking companies that lose money are riskier than those that make money. And the fact is that over the last twelve months Zai Lab lost money at the earnings before interest and tax (EBIT) line. Indeed, in that time it burnt through US$223m of cash and made a loss of US$339m. While this does make the company a bit risky, it's important to remember it has net cash of US$602.5m. That kitty means the company can keep spending for growth for at least two years, at current rates. With very solid revenue growth in the last year, Zai Lab may be on a path to profitability. By investing before those profits, shareholders take on more risk in the hope of bigger rewards. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. For example, we've discovered 1 warning sign for Zai Lab that you should be aware of before investing here.

统计学上,亏损的公司比盈利的公司更具有风险性。事实上,在过去的12个月中,再鼎医药在利息和税前利润(EBIT)方面亏损。在那个时间里,它烧去了2.23亿美元的现金,亏损了3.39亿美元。虽然这使得该公司有些冒险,但重要的是要记住,它拥有60250万美元的净现金。这笔钱意味着该公司至少可以以当前的速度持续用于成长两年。在过去一年里,再鼎医药的收入增长非常强劲,可能在走向盈利之路。通过在盈利之前进行投资,股东承担了更多的风险,希望获得更大的回报。毫无疑问,我们从资产负债表中了解最多的债务。然而,并非所有的投资风险都存在于资产负债表中,远远不止这些。例如,我们在此发现了1个再鼎医药的警示标志,您在投资之前应该了解这些标志。

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

说到底,有时更容易关注那些甚至不需要债务的公司。读者可以免费查看零净债务增长股票列表,立即获得。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发